Wells Fargo & Company Issues Positive Forecast for Maravai LifeSciences (NASDAQ:MRVI) Stock Price

Key Points

• Wells Fargo raised Maravai LifeSciences’ price target from $5.50 to $6.50 and maintained an “overweight” rating, implying 12.77% upside from the prior close.
• Analyst sentiment remains mixed: three analysts rate the stock a Buy and two rate it a Sell, producing an overall “Hold” consensus with an average target of $5.83.
• Maravai reported quarterly revenue of $65.84 million and earnings of $0.01 per share, beating consensus estimates, though the company continues to post negative net margins and return on equity.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) had its price objective boosted by equities research analysts at Wells Fargo & Company from $5.50 to $6.50 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's price target points to a potential upside of 12.77% from the stock's previous close.

Other research analysts have also issued reports about the stock. UBS Group restated a "reduce" rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Weiss Ratings upgraded Maravai LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, May 29th. Wall Street Zen lowered Maravai LifeSciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating and set a $6.00 target price on shares of Maravai LifeSciences in a research report on Friday, May 8th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $5.83.

Maravai LifeSciences Price Performance

MRVI traded down $0.49 during trading on Friday, reaching $5.76. 763,613 shares of the company were exchanged, compared to its average volume of 2,139,469. Maravai LifeSciences has a 12-month low of $2.03 and a 12-month high of $7.44. The company's 50-day moving average is $5.95 and its two-hundred day moving average is $4.37. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -8.03 and a beta of 0.63.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The firm had revenue of $65.84 million for the quarter, compared to analysts' expectations of $53.00 million. Research analysts forecast that Maravai LifeSciences will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the transaction, the general counsel owned 360,767 shares in the company, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company's stock valued at $27,000 after buying an additional 3,209 shares during the period. Virtu Financial LLC purchased a new position in shares of Maravai LifeSciences in the fourth quarter valued at about $34,000. Insigneo Advisory Services LLC bought a new position in shares of Maravai LifeSciences during the fourth quarter valued at about $34,000. Quantessence Capital LLC bought a new position in shares of Maravai LifeSciences during the third quarter valued at about $31,000. Finally, Stifel Financial Corp purchased a new stake in shares of Maravai LifeSciences during the fourth quarter worth about $36,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source